特宝生物(688278) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥345,009,951.29, representing a year-on-year increase of 60.16%[4] - The net profit attributable to shareholders was ¥57,452,423.77, reflecting a growth of 67.90% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥75,548,263.15, which is an increase of 92.45% year-on-year[4] - Basic earnings per share were ¥0.14, up 75.00% compared to the same quarter last year[4] - Total operating revenue for Q1 2022 reached ¥345,009,951.29, a significant increase of 60.1% compared to ¥215,410,044.58 in Q1 2021[16] - Net profit for Q1 2022 was ¥57,452,423.77, representing a 67.9% increase from ¥34,217,953.38 in Q1 2021[17] - The total equity attributable to shareholders increased to ¥1,218,712,834.06 in Q1 2022, up from ¥1,161,260,410.29 in Q1 2021, indicating strong financial health[15] - Total comprehensive income for the current period is 57,452,423.77, compared to 34,217,953.38 in the previous period, indicating a strong performance[19] Cash Flow - The net cash flow from operating activities reached ¥82,949,425.82, marking a 48.50% increase from the previous year[4] - Cash inflow from operating activities for Q1 2022 is 371,792,629.73, compared to 264,429,445.76 in Q1 2021, reflecting a growth of approximately 40.5%[21] - The net cash flow from operating activities is 82,949,425.82, an increase from 55,859,650.78 in the previous year, showing a growth of about 48.5%[21] - Cash inflow from investment activities is 277,720,614.85, down from 383,206,534.94 in the previous year, indicating a decrease of approximately 27.6%[22] - The net cash flow from investment activities is 125,045,262.34, significantly up from 35,300,985.32 in the previous year, marking an increase of over 254%[22] - The net increase in cash and cash equivalents for the current period is 206,281,746.86, compared to 90,300,212.08 in the previous period, representing a growth of approximately 128.5%[22] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,491,411,760.77, a 4.72% increase from the end of the previous year[5] - The company's total assets increased to ¥1,491,411,760.77 in Q1 2022, up from ¥1,424,174,930.07 in Q1 2021, reflecting a growth of 4.7%[15] - Current liabilities amounted to ¥187,820,312.35 in Q1 2022, an increase of 5.0% from ¥177,227,273.41 in Q1 2021[15] Research and Development - R&D investment totaled ¥40,936,298.58, which is 11.87% of operating revenue, a decrease of 2.96 percentage points year-on-year[5] - Research and development expenses for Q1 2022 were ¥20,347,219.38, up from ¥17,184,346.04 in Q1 2021, indicating a focus on innovation[17] Shareholder Information - The number of shares held by the top shareholder, Yang Ying, is 138,077,266, representing 33.94% of the total shares[10] - The second-largest shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., holds 85,700,114 shares, accounting for 21.07%[10] - The company has no reported related party transactions among the top ten shareholders[11] - The company has a total of 4,000,000 shares held under a collective asset management plan, indicating active participation in strategic investments[11] Inventory and Current Assets - The total current assets reached RMB 856.92 million, compared to RMB 834.42 million at the end of 2021, indicating a slight increase of 2.1%[13] - The company's inventory stood at RMB 118.47 million, showing a marginal increase from RMB 116.49 million in the previous year[13] - The company’s accounts receivable decreased to RMB 183.03 million from RMB 186.37 million, reflecting a decline of 1.8%[13] Community Commitment - The company made cash donations totaling RMB 2.63 million during the reporting period, as part of its commitment to public welfare projects[12] - The company has committed to donate a total of RMB 20 million to the China Hepatitis Prevention Foundation over a period ending June 30, 2027, with an additional RMB 17.74 million pledged in January 2022[12] Market Performance - The company experienced a significant increase in sales revenue due to improved market penetration of its products, particularly in hepatitis B treatment[8] - The overall expense ratio has decreased, contributing to the increase in profit alongside revenue growth[8] - The company reported a significant increase in sales expenses, which reached ¥173,460,312.73 in Q1 2022, compared to ¥108,808,481.49 in Q1 2021, reflecting aggressive market expansion efforts[17] Strategic Focus - The company has made significant investments in new technologies and products, although specific figures were not disclosed in the report[20] - The company has not reported any net profit from the merged entity prior to the merger, maintaining a focus on organic growth[20]